Previous 10 | Next 10 |
home / stock / eprx:cc / eprx:cc news
Eupraxia Pharmaceuticals Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$22,287,125 Canada NewsWire /NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ VICTORIA, BC , Aug. 18, 2023 /CNW/ - Eupraxi...
Eupraxia Pharmaceuticals Reports Second Quarter 2023 Financial Results Canada NewsWire VICTORIA, BC , Aug. 11, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innova...
Eupraxia Pharmaceuticals Announces a Non-Brokered Private Placement of up to C$22 Million Canada NewsWire /NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ VICTORIA, BC , Aug. 4, 2023 /CNW/ - Eupraxia Pharmaceuticals ...
Eupraxia Pharmaceuticals Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial with EP-104IAR Canada NewsWire Met primary and three key secondary endpoints Data support clinically meaningful and durable pain relief Pharmacokinetic and safety data support p...
Eupraxia Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus Canada NewsWire VICTORIA, BC , June 15, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) today announced that it has filed and obtained a receipt fo...
Eupraxia Pharmaceuticals Receives U.S. FDA Fast Track Designation for EP-104IAR in Treatment of Osteoarthritis Canada NewsWire VICTORIA, BC , June 13, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinic...
Eupraxia Pharmaceuticals Doses First Patient in Phase 1b/2a Eosinophilic Esophagitis Trial Canada NewsWire VICTORIA, BC , June 8, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology com...
Eupraxia Pharmaceuticals Announces Last Patient Last Visit in Phase 2 Osteoarthritis Clinical Trial of EP-104IAR Canada NewsWire VICTORIA, BC , May 25, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-s...
Eupraxia Pharmaceuticals Announces Appointment of Dr. Mark Kowalski as Chief Medical Officer Canada NewsWire VICTORIA, BC , May 18, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology c...
Eupraxia Pharmaceuticals Reports First Quarter 2023 Financial Results Canada NewsWire VICTORIA, BC , May 11, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an inn...
News, Short Squeeze, Breakout and More Instantly...
Eupraxia Pharmaceuticals Inc. Company Name:
EPRX:CC Stock Symbol:
TSXC Market:
Eupraxia Pharmaceuticals Inc. Website:
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo Canada NewsWire VICTORIA, BC , July 8, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnolo...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 Canada NewsWire Osteoarthritis ("OA") is the leading cause of disability in older adults. The U.S. Centers for Disease Control an...
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders Canada NewsWire VICTORIA, BC , June 6, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. (" Eupraxia " or the " Company ") (TSX: EPRX) (NASDAQ: EPRX), a cli...